Mild cognitive impairment is the intermediate state between normal aging and dementia. The criteria: cognitive decline reported by patient, informant, or clinician; objective evidence of impairment in one or more cognitive domains; preserved independence in functional activities (a key differentiator from dementia); cognitive deficits not severe enough to interfere significantly with daily function.
MCI vs normal aging: normal aging produces measurable changes in some cognitive domains (processing speed, memory retrieval) that remain within age-expected ranges. MCI involves performance below age-expected, with the patient or family noticing change from baseline. The distinction is clinical and sometimes requires longitudinal observation.
MCI vs dementia: dementia requires substantial impairment in daily function — the patient cannot manage finances, medications, or complex tasks independently. MCI patients can still do these things, perhaps with more effort or strategies, but daily life is largely preserved.
Two main subtypes:
Amnestic MCI — memory is the primary affected domain. Higher conversion rate to Alzheimer's disease (approximately 10-15% per year in clinical samples).
Non-amnestic MCI — other domains primarily affected (executive function, language, visuospatial). More heterogeneous outcomes — can progress to FTD, LBD, vascular dementia, or remain stable.
Workup of MCI: comprehensive cognitive testing (formal neuropsychological evaluation when feasible — quantifies the pattern more precisely than office testing), structural MRI to assess for vascular contribution and atrophy patterns, basic labs (TSH, B12, basic metabolic), consider biomarker testing for amyloid (CSF or PET) particularly if anti-amyloid therapy considered.
Management of MCI:
Modifiable risk factors: cardiovascular risk factor management (hypertension, diabetes, lipids, smoking, atrial fibrillation), hearing aids if hearing loss present (substantial evidence that hearing loss accelerates cognitive decline), treatment of sleep apnea, vitamin D repletion if deficient, treatment of depression.
Cognitive engagement: mentally stimulating activities, social engagement, education and lifelong learning all associated with better cognitive trajectory.
Physical exercise: aerobic exercise is the intervention with the most evidence for slowing conversion of MCI to dementia. Multiple trials show meaningful effect on cognitive trajectory and reduced conversion risk.
Cholinesterase inhibitors: not FDA-approved for MCI alone; some clinicians use off-label, evidence mixed. Consider if amyloid biomarker-positive in research or specialty settings.
Anti-amyloid antibodies: increasingly an option for amyloid-positive MCI patients (early Alzheimer's) — see anti-amyloid therapy concept.
Outcomes are heterogeneous. Some patients with MCI remain stable for years. Some return to normal cognition (often reflecting transient factors). Some progress to dementia. The 5-year conversion rate to dementia in clinical samples is roughly 30-50%, but population samples show lower rates.
When you encounter an older adult with mild cognitive complaints and objective testing showing impairment, MCI is the diagnosis to consider. The intervention is real — aggressive risk factor management, exercise, social engagement, treatment of contributing conditions. Many patients can substantially affect their cognitive trajectory.